BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 29752320)

  • 21. Lung Cancer Genomics.
    Parikh AR
    Acta Med Acad; 2019 Apr; 48(1):78-83. PubMed ID: 31264435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. From Uniplex to Multiplex Molecular Profiling in Advanced Non-Small Cell Lung Carcinoma.
    Ileana EE; Wistuba II; Izzo JG
    Cancer J; 2015; 21(5):413-24. PubMed ID: 26389767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis.
    Dacic S
    Expert Rev Mol Diagn; 2007 Jan; 7(1):77-86. PubMed ID: 17187486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.
    Sacher AG; Dahlberg SE; Heng J; Mach S; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Mar; 2(3):313-20. PubMed ID: 26720421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Tumor Board Improves Outcomes for Hispanic Patients With Advanced Solid Tumors.
    Sotelo-Rodríguez C; Vallejo-Ardila D; Ruiz-Patiño A; Chamorro DF; Rodríguez J; Moreno-Pérez DA; Carranza H; Otero J; Vargas C; Archila P; Rojas L; Zuluaga J; Rubio C; Ordóñez-Reyes C; Garcia-Robledo JE; Mejía S; Jaller E; Arrieta O; Cardona AF
    JCO Glob Oncol; 2024 Jan; 10():e2300011. PubMed ID: 38237094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
    Koopman B; Groen HJM; Ligtenberg MJL; Grünberg K; Monkhorst K; de Langen AJ; Boelens MC; Paats MS; von der Thüsen JH; Dinjens WNM; Solleveld N; van Wezel T; Gelderblom H; Hendriks LE; Speel EM; Theunissen TE; Kroeze LI; Mehra N; Piet B; van der Wekken AJ; Ter Elst A; Timens W; Willems SM; Meijers RWJ; de Leng WWJ; van Lindert ASR; Radonic T; Hashemi SMS; Heideman DAM; Schuuring E; van Kempen LC
    Oncologist; 2021 Aug; 26(8):e1347-e1358. PubMed ID: 33111480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
    Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
    Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic alterations in lung adenocarcinoma.
    Devarakonda S; Morgensztern D; Govindan R
    Lancet Oncol; 2015 Jul; 16(7):e342-51. PubMed ID: 26149886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data.
    Wang E; Zaman N; Mcgee S; Milanese JS; Masoudi-Nejad A; O'Connor-McCourt M
    Semin Cancer Biol; 2015 Feb; 30():4-12. PubMed ID: 24747696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.
    Vigneswaran J; Tan YH; Murgu SD; Won BM; Patton KA; Villaflor VM; Hoffman PC; Hensing T; Hogarth DK; Malik R; MacMahon H; Mueller J; Simon CA; Vigneswaran WT; Wigfield CH; Ferguson MK; Husain AN; Vokes EE; Salgia R
    Oncotarget; 2016 Apr; 7(14):18876-86. PubMed ID: 26934441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.
    Young G; Wang K; He J; Otto G; Hawryluk M; Zwirco Z; Brennan T; Nahas M; Donahue A; Yelensky R; Lipson D; Sheehan CE; Boguniewicz AB; Stephens PJ; Miller VA; Ross JS
    Cancer Cytopathol; 2013 Dec; 121(12):688-94. PubMed ID: 23893923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NUT Midline Carcinoma of the Lung in a Six-Year-Old Child.
    Karakuş E; Poyraz A; Oğuz Erdogan AS; Emir S; Özyörük D
    Fetal Pediatr Pathol; 2017 Dec; 36(6):472-474. PubMed ID: 29220605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.
    Garofalo A; Sholl L; Reardon B; Taylor-Weiner A; Amin-Mansour A; Miao D; Liu D; Oliver N; MacConaill L; Ducar M; Rojas-Rudilla V; Giannakis M; Ghazani A; Gray S; Janne P; Garber J; Joffe S; Lindeman N; Wagle N; Garraway LA; Van Allen EM
    Genome Med; 2016 Jul; 8(1):79. PubMed ID: 27460824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical efficacy and possible applications of genomics in lung cancer.
    Alharbi KK
    Asian Pac J Cancer Prev; 2015; 16(5):1693-8. PubMed ID: 25773789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current clinical application of genomic and proteomic profiling in non-small-cell lung cancer.
    Tanvetyanon T; Creelan BC; Chiappori AA
    Cancer Control; 2014 Jan; 21(1):32-9. PubMed ID: 24357739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
    Tafe LJ; Gorlov IP; de Abreu FB; Lefferts JA; Liu X; Pettus JR; Marotti JD; Bloch KJ; Memoli VA; Suriawinata AA; Dragnev KH; Fadul CE; Schwartz GN; Morgan CR; Holderness BM; Peterson JD; Tsongalis GJ; Miller TW; Chamberlin MD
    Oncologist; 2015 Sep; 20(9):1011-8. PubMed ID: 26205736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer.
    Laufer-Geva S; Rozenblum AB; Twito T; Grinberg R; Dvir A; Soussan-Gutman L; Ilouze M; Roisman LC; Dudnik E; Zer A; Rotem O; Lanman RB; Peled N
    J Thorac Oncol; 2018 Nov; 13(11):1705-1716. PubMed ID: 30121392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer.
    Vignot S; Frampton GM; Soria JC; Yelensky R; Commo F; Brambilla C; Palmer G; Moro-Sibilot D; Ross JS; Cronin MT; André F; Stephens PJ; Lazar V; Miller VA; Brambilla E
    J Clin Oncol; 2013 Jun; 31(17):2167-72. PubMed ID: 23630207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer.
    Planchard D; Remon J; Nowak F; Soria JC
    Am Soc Clin Oncol Educ Book; 2017; 37():12-17. PubMed ID: 28561640
    [No Abstract]   [Full Text] [Related]  

  • 40. Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck.
    Chau NG; Hurwitz S; Mitchell CM; Aserlind A; Grunfeld N; Kaplan L; Hsi P; Bauer DE; Lathan CS; Rodriguez-Galindo C; Tishler RB; Haddad RI; Sallan SE; Bradner JE; French CA
    Cancer; 2016 Dec; 122(23):3632-3640. PubMed ID: 27509377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.